 PONTE VEDRA, Fla., April 22, 2021 GLOBE NEWSWIRE -- Treace Medical Concepts, Inc. Treace Nasdaq: TMCI, a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus commonly known as bunions, today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of 17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately 106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Treace and the selling stockholders have granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock up to 703,125 additional shares from Treace and up to 984,375 additional shares from the selling stockholders at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on April 23, 2021 under the ticker symbol TMCI. The offering is expected to close on April 27, 2021, subject to satisfaction of customary closing conditions. 